For example, 36% of BRAF-mutated IHCC has previously been described to be coaltered with MTAP-loss, which our current study re-capitulates with an enrichment of BRAF mutations in MTAP-loss IHCC.41 These patients with both BRAF mutations and MTAP-loss would be candidates to sequence BRAF inhibitors, which have tumor-agnostic FDA approval, with a clinical trial of PRMT5 or MAT2A inhibitors on progression, and vice versa.42 Here, MAT2A is linked to neoplasm.